One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
KasparBrochMD, PhDab?Anne KristineAnstensrudMDac?SindreWoxholtMDdeKapilSharmaMDfIngvild MariaT?llefsenMDfBj?rnBendzMD, PhDacSvendAakhusMD, PhDdeThorUelandPhDghBrage H?yemAmundsenMD, PhDdeJan KristianDam?sMD, PhDijErlend SturleBergMDaElisabethBj?rkelundRNaChristinaBendzRNaEinarHoppMD, PhDkOlaKlevelandMD, PhDdeKnut HaakonStens?thMD, PhDelAndersOpdahlMD, PhDaNils-EinarKl?wMD, PhDcmIngebj?rgSeljeflotPhDcfnGeir ?ysteinAndersenMD, PhDfnRuneWisethMD, PhDdeP?lAukrustMD, PhDco†LarsGullestadMD, PhDabc†
doi : 10.1016/j.jacc.2021.02.049
Volume 77, Issue 15, 20 April 2021, Pages 1845-1855
Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, as much as 50% of the loss of viable myocardium may be attributed to the reperfusion injury and the associated inflammatory response.
Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and Prevention?
Paul MRidkerMD, MPH
doi : 10.1016/j.jacc.2021.02.060
Volume 77, Issue 15, 20 April 2021, Pages 1856-1858
Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation Myocardial Infarction
Kyung HoonChoMD, PhDaXiongyiHanMDaJoon HoAhnMDaDae YoungHyunMDaMin ChulKimMD, PhDabDoo SunSimMD, PhDabYoung JoonHongMD, PhDabJu HanKimMD, PhDabYoungkeunAhnMD, PhDabJin YongHwangMD, PhDcSeok KyuOhMD, PhDdKwang SooChaMD, PhDeCheol UngChoiMD, PhDfKyung-KukHwangMD, PhDgHyeon CheolGwonMD, PhDhMyung HoJeongMD, PhDabKAMIR-NIH Investigators
doi : 10.1016/j.jacc.2021.02.041
Volume 77, Issue 15, 20 April 2021, Pages 1859-1870
Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited.
The Edge of Time in Acute Myocardial Infarction?
Harold L.DauermanMDaBorjaIbanezMD, PhDbcd
doi : 10.1016/j.jacc.2021.03.003
Volume 77, Issue 15, 20 April 2021, Pages 1871-1874
Effects of Fluoroquinolones on Outcomes of Patients With Aortic Dissection or Aneurysm
Shao-WeiChenMD, PhDabYi-HsinChanMDcVictorChien-Chia WuMDcYu-TingChengMDaDong-YiChenMDcChia-PinLinMDcKuo-ChunHungMDcShang-HungChangMD, PhDbcPao-HsienChuMDcAn-HsunChouMD, PhDd
doi : 10.1016/j.jacc.2021.02.047
Volume 77, Issue 15, 20 April 2021, Pages 1875-1887
Recent population-based studies have revealed that the use of fluoroquinolones (FQs) is associated with an increased risk of aortic dissection (AD) and aneurysm (AA). However, no evidence is available on whether FQs increase adverse events in patients who had been diagnosed with AD or AA.
Fluoroquinolones in Patients With Aortic Aneurysms or Dissections: Pouring Gasoline on a Fire?
Scott A.LeMaireMD
doi : 10.1016/j.jacc.2021.03.004
Volume 77, Issue 15, 20 April 2021, Pages 1888-1890
Endovascular Aortic Repair in Nonagenarian Patients
Carlota F.PrendesMDaAnandDayamaMD, PhDbJean M.PannetonMD, PhDcJanStanaMD, PhDaBarbaraRantnerMD, PhDaFrancisco?lvarez MarcosMD, PhDcKevinManiMD, PhDdAndersWanhainenMD, PhDdNikolaosTsilimparisMD, PhDa
doi : 10.1016/j.jacc.2021.02.042
Volume 77, Issue 15, 20 April 2021, Pages 1891-1899
The increasing proportion of elderly patients being treated for abdominal aortic aneurysm (AAA) in the endovascular era is controversial.
Endovascular Aortic Repair in Nonagenarians: Select Well and Time Appropriately?
Gilbert H.L.TangMD, MSc, MBAaRami O.TadrosMDb
doi : 10.1016/j.jacc.2021.02.046
Volume 77, Issue 15, 20 April 2021, Pages 1900-1902
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
Azita H.TalasazPharmDabParhamSadeghipourMDcHessamKakavandPharmDabMaryamAghakouchakzadehPharmDaElahehKordzadeh-KermaniPharmDaBenjamin W.Van TassellPharmDdeAzinGheymatiPharmDaHamidAriannejadMDbSeyed HosseinHosseiniPharmDaSepehrJamalkhanicMichelleSholzbergMDCM, MScfgManuelMonrealMD, PhDhDavidJimenezMD, PhDiGregoryPiazzaMD, MSjSahil A.ParikhMDklAjay J.KirtaneMD, SMklJohn W.EikelboomMBBSmJean M.ConnorsMDn…BehnoodBikdeliMD, MSjkw
doi : 10.1016/j.jacc.2021.02.035
Volume 77, Issue 15, 20 April 2021, Pages 1903-1921
Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week
James L.JanuzziJr.MDabJohn M.CantyMDcSaumyaDasMD, PhDaChristopher R.DeFilippiMDdGary A.GintantPhDeDavid E.GutsteinMDfAllanJaffeMDgEmily P.KaushikPhDhChristopherLeptakMD, PhDiCyrusMehtaPhDjIleanaPinaMD, MPHkThomas J.PovsicMD, PhDlCurtisRambaranMBBS, MDmRhonda F.RhyneBPharm, MBAnMaribelSalasMD, DSc, MScmoVictor C.ShiMDpJacob A.UdellMD, MPHqEllis F.UngerMDr…Jonathan H.SeltzerMD, MBAt
doi : 10.1016/j.jacc.2021.02.040
Volume 77, Issue 15, 20 April 2021, Pages 1922-1933
The momentum of cardiovascular drug development has slowed dramatically. Use of validated cardiac biomarkers in clinical trials could accelerate development of much-needed therapies, but biomarkers have been used less for cardiovascular drug development than in therapeutic areas such as oncology. Moreover, there are inconsistences in biomarker use in clinical trials, such as sample type, collection times, analytical methods, and storage for future research. With these needs in mind, participants in a Cardiac Safety Research Consortium Think Tank proposed the development of international guidance in this area, together with improved quality assurance and analytical methods, to determine what biomarkers can reliably show. Participants recommended the development of systematic methods for sample collection, and the archiving of samples in all cardiovascular clinical trials (including creation of a biobank or repository). The academic and regulatory communities also agreed to work together to ensure that published information is fully and clearly expressed.
Considerations for Racial Diversity in the Cardiology Workforce in the United States of America
Amber E.JohnsonMD, MS, MBAabMehretBirru TalabiMD, PhDaElianaBonifacinoMD, MSaAlison J.CulybaMD, PhD, MPHaNaudia L.JonassaintMDaMelonie A.NanceMDabG. SarahNapoéMDaOladipupoOlafiranyeMD, MSabSylviaOwusu-AnsahMDaTomeka L.SuberMD, PhDa
doi : 10.1016/j.jacc.2021.02.043
Volume 77, Issue 15, 20 April 2021, Pages 1934-1937
ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee
ElissaDrigginMD(Co-Chair, Writing Committee)Thomas M.MaddoxMD, MSc, FACC(Co-Chair, Writing Committee)Keith C.FerdinandMD, FACC(Writing Committee Member)James N.KirkpatrickMD, FACC(Writing Committee Member)BonnieKyMD, MSCE, FACC(Writing Committee Member)Alanna A.MorrisMD, MSc, FACC(Writing Committee Member)J. BrendanMullenBSFS(Writing Committee Member)Sahil A.ParikhMD, FACC(Writing Committee Member)Daniel M.PhilbinJr.MD, FACC(Writing Committee Member)MuthiahVaduganathanMD, MPH, FACC(Writing Committee Member)
doi : 10.1016/j.jacc.2021.02.017
Volume 77, Issue 15, 20 April 2021, Pages 1938-1948
ACC.21 Virtual: Experience an Opportunity to Reconnect and Engage
AthenaPoppasMD, MACC(Immediate Past President, American College of Cardiology)Pamela B.MorrisMD, FACC(Annual Scientific Session Chair, American College of Cardiology)DouglasDrachmanMD, FACC(Annual Scientific Session Vice-Chair, American College of Cardiology)
doi : 10.1016/j.jacc.2021.03.011
Volume 77, Issue 15, 20 April 2021, Pages 1949-1951
Greater Splanchnic Nerve Stimulation in Heart Failure With Preserved Ejection Fraction
MaratFudimMD, MHSPetrNeuzilMD, PhDFilipMalekMDZoar J.EngelmanPhDVivek Y.ReddyMD
doi : 10.1016/j.jacc.2021.02.048
Volume 77, Issue 15, 20 April 2021, Pages 1952-1953
Temporary Mechanical Circulatory Support: An Intervention in Need of a Strategy
AndrewMorley-SmithMDDavidQuinnMDHoong SernLimMD
doi : 10.1016/j.jacc.2021.01.054
Volume 77, Issue 15, 20 April 2021, Page 1954
Reply: Temporary Mechanical Circulatory Support: An Intervention in Need of a Strategy
DiyarSaeedMDEvgenijPotapovMDDavidSchibilskyMDArturLichtenbergMDJanGummertMD
doi : 10.1016/j.jacc.2021.01.055
Volume 77, Issue 15, 20 April 2021, Pages 1954-1955
Reliable Diagnosis of Hypertension: What Is the Best Approach?
MarijanaTadicMD, PhDCesareCuspidiMD
doi : 10.1016/j.jacc.2020.12.070
Volume 77, Issue 15, 20 April 2021, Pages 1955-1956
Reply: Reliable Diagnosis of Hypertension: What Is the Best Approach?
Joseph E.SchwartzPhDPaulMuntnerPhDDaichiShimboMD
doi : 10.1016/j.jacc.2021.02.018
Volume 77, Issue 15, 20 April 2021, Pages 1956-1957
